Journal Club: A New Wave In Positive Psychiatry With Four Landmark Journal Articles

We launch a 'Psychiatry Journal Club' series built to get us reading again and to translate major psychiatry papers into practical, humane care.  We walk through four landmark studies that reshape how we think about schizophrenia treatment, suicidal crisis care, metabolic health, and relapse prevention through a Positive Psychiatry lens.  • why dopamine-first antipsychotics often miss negative symptoms and cognition while harming metabolic health  • how xanomeline plus trospium (KarXT/Cobenfy) targets M1 and M4 muscarinic receptors without direct D2 binding  • what the Emergent 3 phase 3 trial shows on PANSS change, onset by week two, and a cleaner metabolic and EPS profile  • why preserving reward circuitry and reducing dysphoria can change adherence conversations in schizophrenia  • the clinical gap between acute suicidality and multi-week SSRI and SNRI latency  • how intranasal esketamine rapidly affects glutamate circuits, AMPA signaling, mTORC1, and BDNF-driven synaptogenesis  • Aspire 2 outcomes at four hours and 24 hours, plus monitoring for dissociation and blood pressure changes  • how GLP-1 receptor agonists can reverse antipsychotic-induced weight gain and improve BMI, waist circumference, glucose, and lipids  • brain-gut-reward and neuroinflammation pathways that connect GLP-1s to neuropsychiatry  • why early long-acting injectables reduce relapse risk, hospitalizations, and functional decline in early schizophrenia  • how relapse biology and oral medication level swings support a neuroprotection argument for LAIs  Let’s together keep reading. We must read more, folks.  www.JainUplift.com